BioNTech
phase a anti tumor activity in immune recurrent refractory expansion | BioNTech
Company
Deck Type
Sector
Industry
Deck date
November 2020
Slide
20 of 25
Related slides by other companies
Genelux
Investor Presentation
December 2023
phase anti tumor activity as leading into combination a | Genelux
Genelux
Investor Presentation
July 2023
phase anti tumor activity as leading into combination platinum resistant | Genelux
Genelux
Investor Presentation
February 2024
phase anti tumor activity as leading into combination soc aurelia regimen gratis | Genelux
Genelux
Investor Presentation
October 2023
phase anti tumor activity as leading into combination regimen prior prior | Genelux
Other recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Investor Day
June 2022
Results
March 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io